FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a method for producing T-cells for immunotherapy and is applicable in medicine. The proposed method including inactivation of the beta 2-microglobulin (B2M) gene and of at least one gene encoding a T-cell receptor (TCR) component, by means of using targeted rare-cutting endonucleases, allows to produce T-cells for expression of a chimeric antigen receptor (CAR), suitable for allotransplantation and cancer immunotherapy.
EFFECT: improved method for production of T-cells for immunotherapy.
21 cl, 10 dwg, 10 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CELL TARGETING MEDIATED BY CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2783316C2 |
| INSERTION OF TARGET GENE FOR IMPROVED CELLULAR IMMUNOTHERAPY | 2017 |
|
RU2824204C2 |
| MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF | 2013 |
|
RU2663725C2 |
| CD33-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2701341C2 |
| IMMUNE CELLS DEFECTIVE BY Suv39h1 | 2018 |
|
RU2784531C2 |
| CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2014 |
|
RU2727447C2 |
| METHOD OF CONSTRUCTING ALLOGENIC AND DRUG RESISTANT T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2689558C1 |
| METHODS FOR CONSTRUCTING ALLOGENIC AND HIGH-ACTIVITY T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2736616C2 |
| METHODS FOR CONSTRUCTING HIGH-ACTIVITY T-CELLS FOR IMMUNOTHERAPY | 2014 |
|
RU2725542C2 |
| OPTIONS, COMPOSITIONS, AND METHODS FOR USE OF HOMING-ENDONUCLEASE PD-1 | 2017 |
|
RU2781083C2 |
